Feature

New Omicron subvariant is ‘crazy infectious,’ COVID expert warns


 

The newest subvariant of Omicron, XBB.1.5, is so transmissible that everybody is at risk of catching it, even if they’ve already been infected and are fully vaccinated, a health expert told USA Today.

“It’s crazy infectious,” said Paula Cannon, PhD, a virologist at the University of Southern California, Los Angeles. “All the things that have protected you for the past couple of years, I don’t think are going to protect you against this new crop of variants.”

XBB.1.5 is spreading quickly in the United States. It accounted for 27.6% of cases in the country in the week ending on Jan. 7, up from about 1% of cases at one point in December, according to the Centers for Disease Control and Prevention. It’s especially prevalent in the Northeast, now accounting for more than 70% of the cases in that region.

It’s spreading across the globe, too. Maria Van Kerkhove, PhD, technical lead of the World Health Organization, has called XBB.1.5 is “the most transmissible subvariant that has been detected yet.”

Ashish Jha, MD, the White House COVID-19 response coordinator, tweeted a few days ago that the spread of XBB.1.5 is “stunning” but cautioned that it’s unclear if the symptoms of infection will be more severe than for previous variants.

“Whether we’ll have an XBB.1.5 wave (and if yes, how big) will depend on many factors including immunity of the population, people’s actions, etc.,” he tweeted.

He urged people to get up to date on their boosters, wear a snug-fitting mask, and avoid crowded indoor spaces. He noted that people who haven’t been infected recently or haven’t gotten the bivalent booster likely have little protection against infection.

The symptoms for XBB.1.5 appear to be the same as for other versions of COVID-19. However, it’s less common for people infected with XBB.1.5 to report losing their sense of taste and smell, USA Today reported.

A version of this article first appeared on WebMD.com.

Recommended Reading

COVID update: ASH experts discuss thrombosis, immunity
Covid ICYMI
Study of beliefs about what causes cancer sparks debate
Covid ICYMI
SARS-CoV-2 seroprevalence grew rapidly in pandemic’s early waves
Covid ICYMI
Children and COVID: New cases fell as the old year ended
Covid ICYMI
IBD patients have limited protection against Omicron with third vaccine dose
Covid ICYMI
What’s next for COVID? Here’s what to know
Covid ICYMI
Long COVID clinical trials may offer shortcut to new treatments
Covid ICYMI
Gene associated with vision loss also linked to COVID: Study
Covid ICYMI
Advanced Primary Care program boosts COVID-19 results
Covid ICYMI
Autopsies show COVID virus invades entire body
Covid ICYMI